Loading this company
Bristol-Myers Squibb Company
BMYPrices in USD
TickerWorth ScoreA70/100
What we think
Priced below our range of $75.37 to $149.29.A range by design: peer multiples and our researched mid-cycle DCF.
Price
$59.75USD down −$0.82 (−1.35%)
Quoted · Prices are delayed.
Why did it move today?
Nothing we can cite explains today’s move for this company.
Is it cheap?
Our range from 2 models, on today’s numbers
$75.37–$149.29
A range by design: peer multiples and our researched mid-cycle DCF.
What the price needs: revenue growth of -10.1%/yr for 5 years (our model assumes −6.3%).
Led by peer multiples (P/E, EV/EBITDA, P/S) · Cyclical business
Price $59.75Priced · Prices are delayed.
Is it a good business?
- Valuation75 out of 100
- Growth83 out of 100
- Financial health33 out of 100
- Dividend100 out of 100
- Past performance100 out of 100
Bull, base, bear
Our forward range over 12 months is part of Pro. See plans
The street
Analysts’ mean target
$65.63 across 24 analysts
The high and low of the analyst range is part of Pro. See plans
What does it do?
Bristol-Myers Squibb discovers, develops, and sells biopharmaceutical products worldwide, with a focus on oncology, hematology, immunology, cardiovascular, and neuroscience treatments. The company's major products include Opdivo (cancer), Orencia (rheumatoid arthritis), Zeposia (multiple sclerosis), and several other specialty drugs, serving approximately 32,500 employees.
Key stats
52-week range$42.52–$68.64
- Open
- $61.10
- Day high
- $61.43
- Day low
- $59.54
- Previous close
- $60.57
- Volume
- 12,823,530 · 1.11× avg
- Average volume
- 11,584,081
- Market cap
- $122,052,198,400.00
- P/E (TTM)
- 13.16
- Earnings per share
- $4.54
- Beta
- 0.18
Prices are delayed. The feed does not say when these figures were taken.
What’s the latest?
- Reported quarterly or annual results
- Reported shareholder vote results
- Reported quarterly or annual results
- Reported quarterly or annual results
- Issued a public disclosure (Reg FD)
- Disclosed another material event
- Disclosed another material event
Top news
No recent headlines we can cite for this company.
Insider trades
The 90-day buying-and-selling read is part of Pro. See plans
- Gallman CariOption exercise · —
- Gallman CariShares withheld (tax) · $142,601.80
Not investment advice. TickerWorth Score is a model output.